Articles by Andrew W. Hahn, MD
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.